Day 3, Thursday, March 20th, 2025Thursday, 20 March 2025 - ET (Eastern Time, GMT-05:00)

The pricing of rare disease therapies has become increasingly complex and controversial. Unpack the factors shaping the evolving pricing landscape, including the impact of patient access initiatives, payer pressures and the role of value-based pricing models.

• Take a practical look at AI and ML to understand how to best tap into its potential whilst also remaining cautious of its pitfalls
• Learn how AI can play a key role in treatment commercialization (i.e., accelerated drug discovery, patient identification and recruitment, patient engagement, etc.)
• Understand how, in the near term, AI will radically change how we look at disease and what could prevent it from being most helpful
• Explore how AI can empower respective stakeholders, including advocates, caregivers and physicians

Learn about how the Alliance to Cure Cavernous Malformations and the Foundation for Sarcoidosis Research are driving on the ground change. Specific initiatives include clinical trial time off/compensation and FMLA legislation.

Baptist Health’s new dashboard was created to address the challenges associated with Rare Disease patient identification and diagnosis. Striving to give HCPs and manufacturers greater insight into their patients care journey, unpack the life changing data they are utilizing to create this framework and best in class model.

Digital health is transforming the way patients and providers interact, offering new opportunities to improve engagement, streamline care, and enhance satisfaction. This session will explore the evolving role of digital health from, pharma, patient and provider perspectives. We will discuss real-world applications of digital tools used in clinics and pharma, as well as the technologies patients are adopting to manage their health. Topics will include remote patient monitoring, AI-driven tools, patient portals, and telehealth solutions. By examining these innovations, we will highlight how digital health fosters better communication, supports shared decision-making, and ultimately leads to improved health outcomes. Join us for an interactive discussion on the future of digital health and how to optimize its impact.

With the election behind us and a new administration in place, the impact on healthcare legislation and regulatory priorities is coming into focus. This session examines key policy shifts, congressional dynamics and the evolving relationship between government and the (health) life sciences sector.

• Assess how the new administration’s priorities and congressional leadership changes are shaping healthcare policies, including drug pricing, market access, and patient assistance programs.
• Examine the possible implications for industry
• Gain strategic insights into navigating the evolving political landscape, engaging effectively with policymakers